Life sciences senior team
Life Sciences Strategy: Senior Team
Dr. Bell frequently testifies as an expert witness on damages in intellectual property, finance, and antitrust litigation in courts and arbitration proceedings in North America, Europe, and Australia. Dr. Bell’s business consulting engagements focus on the economics of business strategy, working with firms to develop sustainable competitive advantages in specific product markets. He has led numerous projects concerning game theory and competitive strategy, global launch strategy, product pricing and positioning, capital budgeting and real options, and cost-benefit analyses.
Mr. Jeffrey S. Aroy is an experienced consultant, seasoned senior executive, and strong strategic thinker with more than 20 years in the industry. His consulting experience focuses on corporate and product strategy, companion diagnostics, strategic marketing, emerging markets, and M&A-oriented growth. Mr. Aroy has helped life sciences companies develop and implement growth strategies in a variety of therapeutic areas across pharmaceuticals, medical devices, and diagnostics.
Robert Broadnax has more than 17 years of pharma/biotech commercialization, sales, and advanced analytics experience ranging from early pipeline to in-line brands with expertise in specialty disease areas, including Oncology, Immunology and Virology.
Mr. Brubacher has 25 years of pharmaceutical and biotech commercialization experience and has led cross-functional marketing and commercial teams during the development and launch of pharmaceutical products. His expertise includes global commercial planning and market strategy, analytics, market simulation, rare diseases, lifecycle management, launch planning, and competitive gaming.
Andrew Butcher is an expert in communications and reputation management. He advises leadership and brand teams on how to maximize the impact of stakeholder relations and communications to drive business strategy and internal change. He consults with life sciences firms on communications strategy, corporate reputation, and market access.
Dr. Iain M. Cockburn is an econometrician and industrial organization economist specializing in the pharmaceutical, biotechnology, and health care industries. His research interests include the economics of innovation, intellectual property, pharmacoeconomics, productivity measurement, competitive strategy, and applied econometrics. He is Professor of Finance and Economics and Richard C. Shipley Professor in Management at the School of Management at Boston University in Boston, MA and a research associate at the National Bureau of Economic Research in Cambridge, MA.
Justus Dehnen has more than 15 years in the industry. His consulting experience focuses on pricing and market access, contracting and loss of exclusivity (LoE) strategy development projects for national and international Life Science companies. He works across multiple therapeutic areas for pharma, biotech, and medical device companies. Mr. Dehnen has helped life science companies to develop and maintain access, pricing, and reimbursement along the product lifecycle from early pipeline to LoE.
Mr. Rhett Johnson has more than 14 years of consulting experience, and he specializes in developing therapeutic area, market access, and growth strategies for clients in the life sciences industry. His extensive strategy consulting experience includes pricing, managed markets, global market access, product and portfolio positioning, competitor analysis, and market research. Other work has included antitrust, litigation support, and policy analysis, primarily in the health care industry.
Ned Kitfield has extensive experience providing commercial decision support for large and small biotech, pharmaceutical, and healthcare companies. While Ned has worked across a broad spectrum of therapeutic categories, he brings particular insight into rare and ultra-orphan diseases. He expertise includes everything from commercialization strategy to advanced analytics and primary market research designed for these often overlooked rare spaces.
Mr. Matthew Majewski has a track record of providing life science clients with analytically based solutions to their strategic issues. He has led a range of strategy engagements from product related topics to corporate challenges.
Andrew Parece is a vice president in the Life Sciences Practice. With more than 30 years of consulting experience, Mr. Parece specializes in pricing and competitive strategy, quantitative analysis, modeling, and market research, primarily in the pharmaceutical, biotech, and life sciences industries. His work in pharmaceuticals has focused on pricing, contracting, market access, and brand/franchise strategy. He has managed competitive assessments and product launch strategy assignments for several high-profile products.
David Persampieri has extensive experience in providing strategic and operational services to clients in a number of industries. His expertise includes strategic planning, competitive analysis, pricing strategy, product/market strategy, customer relations, financial analysis, and technology management, as well as manufacturing and distribution strategy.
Peter Rankin specializes in the economic and strategic evaluation of the pharmaceutical and health care industries. Dr. Rankin’s pharmaceutical research includes assessment of patent extension antitrust claims, class certification analysis, monetary damages from intellectual property disputes, evaluation of blood/plasma market dynamics, product line valuation, and product reimbursement strategies. His health industry research includes analysis of attempted monopolization, demand for medical services, and the cost implications of antitrust waivers for health care providers.
Elizabeth Rountree has 20+ years of customer insights experience (data analytics, primary market research) in biopharmaceuticals as well as in-depth expertise in neuroscience and oncology. Prior to joining CRA, she was a co-founder of three life sciences consulting and market research firms: C1 Consulting, Cozint, and HIV Research.
Rob Sederman has 25+ years of data analytics and consulting expertise in pharma/biotech. Prior to joining CRA, he was a co-founder of C1 Consulting and led their effort to develop an Advanced Analytics practice area. Mr. Sederman has held executive positions at ZS Associates and NOP World Health.
James Swayzee is an independent consultant to several life sciences companies in the US and Europe. His current clients are biopharma start-ups in the areas of oncology, neurology, infectious disease, and vascular disease who seek his advice on strategies for corporate and clinical development as well as interactions with industry.
Andrew Tepperman has frequently analyzed damages issues in litigation engagements and has provided economic assessments of market definition, market power, and anticompetitive conduct. He has considerable experience evaluating a range of antitrust issues associated with intellectual property rights.
Dr. Urs Wiedemann specializes in portfolio management and strategy, the evaluation of new technologies, and accelerating marketing and sales. His work is primarily focused on the pharmaceuticals, biotech, and medical devices sector. Prior to joining CRA, he was a partner at CEPTON. Before that, he served as an independent advisor to health care clients both in Europe and abroad. He holds a degree in biology and a PhD in biochemistry.
Tim Wilsdon focuses on projects involving the pharmaceuticals sector and the retail financial services market. As a vice president in CRA’s London office, Mr. Wilsdon is responsible for leading many pharmaceuticals projects in Europe. He commonly talks at European conferences on issues to do with pricing and reimbursement and the economics of innovation. Recently, Mr. Wilsdon has completed studies for PhRMA, LIF, and PIASA on how pharmaceutical markets could be reformed to work more efficiently. Previously, he was responsible for managing an assignment for the European Commission determining whether there was a global crisis in innovation. He has worked on a series of global pharmaceutical projects, recent examples include projects investigating the potential for launching a new Alzheimers and arthritis product and the likely impact of bio-similars in the growth hormone market.
Stephanie Andrews consults with corporations on market and competitive analysis, operations management, and international competition. She has worked on many large-scale engagements, including a market development and strategy assessment and analysis of demand. She has helped develop demand forecasts for a variety of firms.
Mr. Lev Gerlovin has more than 15 years of consulting experience across strategic planning, litigation, and policy spheres. His recent focus has been in leading strategy and litigation engagements for a diverse set of clients, including leading pharmaceutical and biotechnology manufacturers, distributors, health plan providers, and industry groups.
Joanna Lee's consulting experience includes advising pharmaceutical, biotech, and medical device organizations as well as financial institutions. She consults on portfolio strategy, market entry strategy, product launch, life cycle management, global market access and reimbursement, and due diligence across a diverse set of therapeutic areas for prescription drug, OTC, consumer health and device products. Most of Ms. Lee’s engagements have a global focus, with a primary emphasis on the US, EU, and Japan, but she has also done work for clients in emerging markets such as Brazil, China, India, Mexico, and Russia.